information collected; and (4) ways to minimize the burden of the collection of information on applicants and housing associates, including through the use of automated collection techniques or other forms of information technology. Comments may be submitted to OMB in writing at the address listed above.

Dated: October 17, 2005.

By the Federal Housing Finance Board.

#### John P. Kennedy,

General Counsel.

[FR Doc. 05–21148 Filed 10–21–05; 8:45 am] BILLING CODE 6725–01–P

#### **FEDERAL RESERVE SYSTEM**

## Change in Bank Control Notices; Acquisition of Shares of Bank or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than November 8, 2005.

## A. Federal Reserve Bank of Kansas City (Donna J. Ward, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. Alan R. Fairman, DuBois,
Pennsylvania, Beverly A. Fairman,
Ronald L. Fairman, and Ann W.
Fairman, all of Punxsutawney,
Pennsylvania, acting as a group in
concert, to acquire control of New
Mexico Banquest Corporation, parent of
First National Bank of Santa Fe, both in
Santa Fe, New Mexico.

In connection with this application, Johnny P. Crowley, Glorieta, New Mexico, as trustee of the New Mexico Banquest Corporation Employee Stock Ownership Plan Trust, Santa Fe, New Mexico, to acquire control of New Mexico Banquest Corporation, parent of First National Bank of Santa Fe, both in Santa Fe, New Mexico.

Board of Governors of the Federal Reserve System, October 19, 2005.

#### Robert deV. Frierson.

Deputy Secretary of the Board.
[FR Doc. E5–5856 Filed 10–21–05; 8:45 am]

#### **FEDERAL RESERVE SYSTEM**

# Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at http://www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 18, 2005.

## A. Federal Reserve Bank of Chicago (Patrick M. Wilder, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. CenterBank Financial, Inc., Northfield, Illinois; to become a bank holding company by acquiring 100 percent of the voting shares of CenterBank and Trust, National Association (in organization), Deerfield, Illinois. Board of Governors of the Federal Reserve System, October 19, 2005.

#### Robert deV. Frierson,

Deputy Secretary of the Board.
[FR Doc. E5–5855 Filed 10–21–05; 8:45 am]
BILLING CODE 6210–01–S

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Toxicology Program (NTP); Liaison and Scientific Review Office (LSRO); NTP High Throughput Screening Assays Workshop

**AGENCY:** National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH).

**ACTION:** Workshop Announcement and Request for Public Comment.

**SUMMARY:** The NTP has developed and refined a vision for toxicology in the 21st century ("NTP Vision") and a roadmap for implementing its vision ("NTP Roadmap") to strategically place the program at the forefront of providing scientific data and its interpretation for use in public health decision-making (see NTP Web site http:// ntp.niehs.nih.gov select "NTP Vision and Roadmap"). As part of the NTP Roadmap, the NTP will convene a series of workshops, including the High Throughput Screening Assays Workshop, to discuss test methods and approaches that will enhance the program's ability to efficiently evaluate the large number of substances in our environment for which there is little or no information about their potential hazard for human health. This workshop is scheduled for December 14–15, 2005, at the Hyatt Regency Crystal City, 2799 Jefferson Davis Highway, Arlington, VA and will focus on providing information about high throughput screening techniques and the potential utility of this technology for toxicology and the NTP. This meeting is open to the public and attendance is limited only by the space available. Individuals may register to attend the workshop on a first-come, first-served basis per the procedures outlined below. A copy of the agenda and any additional information about the workshop, including background materials and participants, will be posted on the NTP Web site when available (see NTP Web site http:// ntp.niehs.nih.gov select "Meetings and Workshops").

**DATES:** The workshop will be held on December 14–15, 2005. The workshop will begin each day at 8:30 a.m. and end at approximately 5 p.m. on December 14

and approximately 3 p.m. on December 15.

Comments: Written comments should be received by December 5, 2005, to allow time for adequate review before the workshop (see FOR FURTHER INFORMATION CONTACT below). The deadline for registration to present oral comments at the meeting is December 8, 2005.

Registration: Individuals who plan to attend are encouraged to register online at the NTP Web site http:// ntp.niehs.nih.gov/ select "Meetings and Workshops" as soon as possible because seating is limited. Persons needing special assistance, such as sign language interpretation or other reasonable accommodation in order to attend, should contact 919-541-2475 voice, 919-541-4644 TTY (text telephone), through the Federal TTY Relay System at 800–877–8339, or by e-mail to niehsoeeo@niehs.nih.gov. Requests should be made at least 7 days in advance of the event.

**ADDRESSES:** The workshop will be held at the Hyatt Regency Crystal City, 2799 Jefferson Davis Highway, Arlington, VA.

#### FOR FURTHER INFORMATION CONTACT:

Public comments and any other correspondence should be submitted to Dr. Barbara Shane (NTP Liaison and Scientific Review Office, NIEHS, P.O. Box 12233, MD A3–01, Research Triangle Park, NC 27709; telephone: 919–541–4253, fax: 919–541–0295; or e-mail: shane@niehs.nih.gov).

#### SUPPLEMENTARY INFORMATION:

#### Background

The High Throughput Screening Assays Workshop will include plenary sessions as well as four simultaneous breakout group sessions for in-depth discussion. Each breakout group will address one of the following topics: (1) The selection of targets and assays for high throughput screening; (2) the conduct of studies including chemical selection, study design, and analytical methods; (3) data storage, analysis, and interpretation; and (4) the application of data from high throughput screening assays in regulatory decision-making. Following the workshop, the NTP will prepare a workshop report and present its proposed strategy to the NTP Board of Scientific Counselors for its consideration and input.

#### **Request for Comments**

Public input at this meeting is invited and time is set aside for the presentation of public comments during the plenary session on December 14. Each organization is allowed one speaker during the public comment period. At least 7 minutes will be allotted to each speaker, and if time permits, may be extended to 10 minutes. Registration for oral comments will also be available onsite, although time allowed for presentation by on-site registrants may be less than that for pre-registered speakers and will be determined by the number of persons who register at the meeting.

Written statements can supplement and may expand the oral presentation. If registering on-site and reading from written text, please bring 40 copies of the statement for distribution and to supplement the record. Written comments received in response to this notice will be posted on the NTP Web site (http://ntp.niehs.nih.gov select "Meetings and Workshops"). Persons submitting written comments should include their name, affiliation, mailing address, phone, fax, e-mail, and sponsoring organization (if any) with the document.

Dated: October 13, 2005.

#### Samuel H. Wilson,

Deputy Director, National Institute of Environmental Health Sciences.

[FR Doc. 05–21130 Filed 10–21–05; 8:45 am]

BILLING CODE 4140-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Office of the Secretary

#### **Findings of Scientific Misconduct**

**AGENCY:** Office of the Secretary, HHS. **ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) and the Acting Assistant Secretary for Health have taken final action in the following case:

Xiaowu Li, MD, PhD, The University of California at San Francisco: On September 16, 2005, the U.S. Public Health Service (PHS) entered into a Voluntary Exclusion Agreement with the University of California at San Francisco (UCSF) and Xiaowu Li, MD, PhD, former postdoctoral fellow at UCSF. Based on the UCSF report and additional analysis conducted by ORI in its oversight review, PHS found that Dr. Li engaged in scientific misconduct in reporting research supported by grants P01 DE13904, "Adhesion and proliferation in oral cancer progression," R01 DE12856, "Oral melanoma alpha v beta 3 expression and metastasis," and R01 DE011930, "Regulatory function of fyn in oral SCC invasion," all funded by the National Institute of Dental and Craniofacial

Research (NIDCR), National Institutes of Health (NIH).

Specifically, PHS found that Dr. Li falsified three images in Figure 5B of a paper, "Laminin-5 promotes cell motility by regulating the function of the integrin  $\alpha 6\beta 1$  in pancreatic cancer," published online in *Carcinogenesis Advance Access*, reporting studies on the role of integrin  $\alpha 6\beta 1$  and laminin on the invasiveness of pancreatic cancer cells and their ability to metastasize.

In all three images, mouse melanoma cells were falsely represented as being human pancreatic carcinoma cells; the cancer cells were falsely represented as having been plated on medium with laminin-1, whereas they were in fact plated on medium with vitronectin; and for two of the three images, the cancer cells were falsely represented as having been stained with anti-integrin  $\beta 1,$  whereas they were actually stained with anti-integrin  $\beta 3.$ 

The misconduct was significant because pancreatic cancer has a poor prognosis for patients, since it tends to invade other tissues and to metastasize early in its course. Knowledge of the factors that facilitate cancer cell invasion and metastasis, which was the focus of the questioned figure and paper, is crucial to attempts to develop better treatments for pancreatic and other cancers. Thus, the falsified figure could have misled other investigators in this important area of medical research.

Dr. Li has entered into a Voluntary Exclusion Agreement (Agreement) in which he has voluntarily agreed, for a period of three (3) years, beginning on September 16, 2005:

- (1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as "covered transactions" as defined in the debarment regulations at 45 CFR Part 76; and
- (2) To exclude himself from serving in any advisory capacity to PHS including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as consultant.

#### FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (301) 443–5330.

#### Chris B. Pascal,

Director, Office of Research Integrity.
[FR Doc. 05–21150 Filed 10–21–05; 8:45 am]
BILLING CODE 4150–31–P